研究所

トップページ研究所研究分野紹介がん標的治療トランスレーショナルリサーチ分野業績

がん標的治療トランスレーショナルリサーチ分野 業績

2023年

  1. Adachi Y, Kimura R, Hirade K, Yanase S, Nishioka Y, Kasuga N, Yamaguchi R, Ebi H. Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nat Cancer. 2023 4:829-843, 2023.
  2. Ebi H. Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment. J Thorac Onc. 18:399-401, 2023.
  3. Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu RH, Mulansari NA, Govind Babu K, Lee MA, Tan CK, Cornelio G, Chong DQ, Chen LT, Tanasanvimon S, Prasongsook N, Yeh KH, Chua C, Sacdalan MD, Sow Jenson WJ, Kim ST, Chacko RT, Syaiful RA, Zhang SZ, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open. 8:101588, 2023.
  4. Hiramatsu K, Matsuda C, Masago K, Toriyama K, Sasaki E, Fujita Y, Haneda M, Ebi H, Shibata N, Hosoda W. Diagnostic utility of DNA integrity number as an indicator of sufficient DNA quality in next-generation sequencing-based genomic profiling. Am J Clin Pathol. 11:aqad046, 2023.
  5. Maeda A, Ando H, Irie K, Hashimoto N, Morishige JI, Fukushima S, Ebi H, Uchida K, Iwata H, Sawaki M. Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18). Anticancer Res. 43:1283-1289, 2023

2022年

  1. Cai J、Jacob S、Kurupi R、Dalton KM.、Coon C、Greninger P、Egan RK.、Stein GT.、Murchie E、McClanaghan J、Adachi Y、Hirade K、Dozmorov M、Glod J、Boikos SA.、Ebi H、Hao H、Caponigro G、Benes CH, Faber AC. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell Reports. 40: 111095-111095, 2022
  2. Su W, Mukherjee R, Yaeger R, Son J, Xu J, Na N, Merna Timaul N, Hechtman J, Paroder V, Lin M, Mattar M, Qiu J, Chang Q, Zhao H, Zhang J, Little M, Adachi Y, Han SW, Taylor BS, Ebi H, Abdel-Wahab O, de Stanchina E, Rudin CM, Jänne PA, McCormick F, Yao Z, Rosen N. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular Cell. S1097-2765(22)00434-8, 2022.
  3. Maeda, A; Ando, H; Irie, K; Hashimoto, N; Morishige, J; Fukushima, S; Okada, A; Ebi,H; Matsuzaki, M; Iwata, H; Sawaki, M. Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. European Journal of Clinical Pharmacology. 78:1239-1247, 2022.

2021年

  1. Adachi Y, Kimura R, HIrade K, Ebi H. Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers. Cancers, 13:5081, 2021
  2. Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Sawada K, Taniguchi H, Fuse N, Nomura S, Fukui M, Matsuda S, Sakamoto Y, Uchigata H, Kitajima K, Kuramoto N, Asakawa T, Olsen S, Odegaard JI, Sato A, Fujii S, Ohtsu A, Yoshino T: Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 27:1899-1903, 2021
  3. Nakasuka F, Tabata S, Sakamoto T, Hirayama A, Ebi H, Yamada T, Umetsu K, Ohishi M, Ueno A, Goto H, Sugimoto M, Nishioka Y, Yamada Y, Tomita M, Sasaki AT, Yano S, Soga T. TGF-β-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. Commun Biol. 4:782, 2021. 
  4. Fairchild CK Jr, Floros KV, Jacob S, Coon CM, Puchalapalli M, Hu B, Harada H, Dozmorov MG, Koblinski JE, Smith SC, Domson G, Leverson JD, Souers AJ, Takebe N, Ebi H, Faber AC, Boikos SA. Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA. Cancers. 13:2310, 2021. 
  5. Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K, Shirasu H, Ebi H, Yamanaka T, Aleshin A, Billings PR, Rabinowitz M, Oki E, Takemasa I, Kato T, Mori M, Yoshino T. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 112:2915-2920, 2021.
  6. Hasegawa H, Taniguchi H, Nakamura Y, Kato T, Fujii S, Ebi H, Shiozawa M, Yuki S, Masuishi T, Kato K, Izawa N, Moriwaki T, Oki E, Kagawa Y, Denda T, Nishina T, Tsuji A, Hara H, Esaki T, Nishida T, Kawakami H, Sakamoto Y, Miki I, Okamoto W, Yamazaki K, Yoshino T. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Sci. 112:314-322, 2021.
  7. Maeda A, Irie K, Hashimoto N, Fukushima S, Ando H, Okada A, Ebi H, Kajita M, Iwata H, Sawaki M. Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. Invest New Drugs. 39:272-277, 2021.

2020年

  1. Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, Ebi H. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 26:5962-5973, 2020.
  2. Costa C, Wang Y, Ly A, Hosono Y, Ellen M, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, Jakubik CT, Henderson LE, Damon LJ, Timonina D, Sanidas I, Pinto CJ, Mino-Kenudson M, Stone JR, Dyson NJ, Ellisen LW, Bardia A, Ebi H, Benes CH, Engelman JA and Juric D. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kalpha inhibitors in breast cancer. Cancer Discov. 2020, 10, 72-85.
  3. Saad MI, McLeod L, Yu L, Ebi H, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ. The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis. Carcinogenesis. 41:527-538, 2020.
  4. Ebi H, Bando H, Taniguchi H, Sunakawa Y, Okugawa Y, Hatanaka Y, Hosoda W, Kumamoto K, Nakatani K, Yamazaki K. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. Cancer Sci. 111:3962-3969, 2020.
  5. Lin, YS; Nakatochi, M; Hosono, Y; Ito, H; Kamatani, Y; Inoko, A; Sakamoto, H; Kinoshita, F; Kobayashi, Y; Ishii, H; Ozaka, M; Sasaki, T; Matsuyama, M; Sasahira, N; Morimoto, M; Kobayashi, S; Fukushima, T; Ueno, M; Ohkawa, S; Egawa, N; Kuruma, S; Mori, M; Nakao, H; Adachi, Y; Okuda, M; Osaki, T; Kamiya, S; Wang, CC; Hara, K; Shimizu, Y; Miyamoto, T; Hayashi, Y; Ebi, H; Kohmoto, T; Imoto, I; Kasugai, Y; Murakami, Y; Akiyama, M; Ishigaki, K; Matsuda, K; Hirata, M; Shimada, K; Okusaka, T; Kawaguchi, T; Takahashi, M; Watanabe, Y; Kuriki, K; Kadota, A; Okada, R; Mikami, H; Takezaki, T; Suzuki, S; Yamaji, T; Iwasaki, M; Sawada, N; Goto, A; Kinoshita, K; Fuse, N; Katsuoka, F; Shimizu, A; Nishizuka, SS; Tanno, K; Suzuki, K; Okada, Y; Horikoshi, M; Yamauchi, T; Kadowaki, T; Yu, H; Zhong, J; Amundadottir, LT; Doki, Y; Ishii, H; Eguchi, H; Bogumil, D; Haiman, CA; Le Marchand, L; Mori, M; Risch, H; Setiawan, VW; Tsugane, S; Wakai, K; Yoshida, T; Matsuda, F; Kubo, M; Kikuchi, S; Matsuo, K. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Nature Communications. 11:3175, 2020.
  6. Kotani, D; Bando, H; Taniguchi, H; Masuishi, T; Komatsu, Y; Yamaguchi, K; Nakajima, T; Satoh, T; Nishina, T; Esaki, T; Nomura, S; Takahashi, K; Iida, S; Matsuda, S; Motonaga, S; Fuse, N; Sato, A; Fujii, S; Ohtsu, A; Ebi, H; Yoshino, T. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ESMO open. 5.e000624, 2020.

2019年

  1. Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z and Ebi H. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. Clin Cancer Res. 25:7089-7097, 2019.
  2. Hosono Y, Masuishi T, Mitani S, Yamaguchi R, Kato S, Yoshino T, Ebi H. Evaluation of ALK fusion newly identified in colon cancer by a comprehensive genomic analysis. JCO Precision Oncology 2019, 3, 1-5.
  3. Ebi H, Bando H. Precision Oncology and the Universal Health Coverage System in Japan. JCO Precision Oncology, 3:1-12,2019.
  4. Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z, Tate MD, Balic JJ, Watkins DN, Cain JE, Bozinovski S, Algar E, Kohmoto T, Ebi H, Ferlin W, Garbers C, Ruwanpura S, Sagi I, Rose-John S and Jenkins BJ. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. EMBO Mol Med. 11:e9976, 2019.
  5. Kondoh C, Horio Y, Hayashi Y, Ebi H, Hida T, Hasegawa Y and Yatabe Y. Anaplastic lymphoma kinase expression in small-cell lung cancer. Histopathology. 75:20-28, 2019.
  6. Saad MI, McLeod L, Yu L, Ebi H, Ruwanpura S, Sagi I, Rose-John S and Jenkins BJ. The ADAM17 Protease Promotes Tobacco Smoke Carcinogen-induced Lung Tumourigenesis. Carcinogenesis. bgz123,2019.
  7. Ebi H, Boikos S, and Faber AC. Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers. Journal of Thoracic Disease. (Suppl 15):S1844-S1846.

2018年

  1. Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene .
  2. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO – ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 29:44-70, 2018.
  3. Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, Bernstein B, Ebi H, Engelman JA, Faber AC.Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM. Clinical Cancer Research 24:197-208, 2018.
  4. Song KA, Hosono Y, Turner C, Jacob S, Lochmann TL, Murakami Y, Patel NU, Ham J, Hu B, Powell KM, Coon CM, Windle BE, Oya Y, Koblinski JE, Harada H, Leverson JD, Souers AJ, Hata AN, Boikos S, Yatabe Y, Ebi H*, Faber AC*. Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target. Clin Cancer Res.

2018年以前

  1. Kitai H, Ebi H*, Tomida S, Floros KV, Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC, Yano S*. Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer. Cancer Discov. 2016 6:754-69, 2016. (*; Co-Corresponding Author)
  2. Kotani H, Ebi H*, Kitai H, Nanjo S, Kita K, Huynh TG, Ooi A, Faber AC, Mino-Kenudson M, Yano S*. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Oncogene 35:3587-97, 2016 (*; Co-Corresponding Author)
  3. Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, Benes CH, Engelman JA*. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. PNAS. 110:21124-9, 2013
  4. Corcoran RB*, Ebi H*, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Pelle PD, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA*. EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. Cancer Discov. 2:227-35, 2012. (Co-first author)
  5. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 121:4311-21, 2011.
  6. Faber AC*, Corcoran RB*, Ebi H*, Sequist LV, Waltman BA, Chung E, Incio J, Digumarhty SR, Pollack SF, Song Y, Muzinkansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gomez H, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA*. BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 1. 352-365, 2011. (Co-first author)